BCL6

Across TCGA pan-cancer cohorts, BCL6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCL6 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BCL6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BCL6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where BCL6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.257	0.680	.001	33	view →
LUAD	DFS	Quartile	All	0.830	0.474	.004	13	view →
LSCC	DFS	Median	III,IV	1.000	0.636	.006	10	view →
GBM	OS	Median	All	0.603	0.230	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCL6–PDAC (OS)

Open the PDAC breakdown →